{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:19:25Z","timestamp":1787242765246,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-43985-9","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:04:08Z","timestamp":1775898248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preparation and evaluation of [64Cu]Cu-labeled bisphosphonate amide of DOTA using reactor-produced 64Cu as an affordable skeletal PET imaging agent"],"prefix":"10.1038","volume":"16","author":[{"given":"Priyalata S. S.","family":"Shetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. V.","family":"Vimalnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourav","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutapa","family":"Rakhit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avik","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipta","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"43985_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/s0959-8049(97)10128-9","volume":"34","author":"RD Rubens","year":"1998","unstructured":"Rubens, R. D. Bone metastases - the clinical problem. Eur. J. Cancer. 34, 210\u2013213. https:\/\/doi.org\/10.1016\/s0959-8049(97)10128-9 (1998).","journal-title":"Eur. J. Cancer"},{"key":"43985_CR2","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"M Drake","year":"2008","unstructured":"Drake, M., Clarke, T., L, B. & Khosla, S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83, 1032\u20131045. https:\/\/doi.org\/10.4065\/83.9.1032 (2008).","journal-title":"Mayo Clin. Proc."},{"key":"43985_CR3","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.2174\/138161210793563572","volume":"16","author":"H Heymann","year":"2010","unstructured":"Heymann, H. Bisphosphonates and bone diseases: Past, present and future. Curr. Pharm. Des. 16, 2948\u20132949. https:\/\/doi.org\/10.2174\/138161210793563572 (2010).","journal-title":"Curr. Pharm. Des."},{"key":"43985_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1258\/0004563011901037","volume":"38","author":"SD Vasikaran","year":"2001","unstructured":"Vasikaran, S. D. Bisphosphonates: An overview with special reference to alendronate. Ann. Clin. Biochem. 38, 608\u2013623. https:\/\/doi.org\/10.1258\/0004563011901037 (2001).","journal-title":"Ann. Clin. Biochem."},{"key":"43985_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1039\/B512310K","volume":"36","author":"S Zhang","year":"2007","unstructured":"Zhang, S., Gangal, G. & Uludag, H. \u2018Magic bullets\u2019 for bone diseases: Progress in rational design of bone-seeking medicinal agents. Chem. Soc. Rev. 36, 507\u2013531. https:\/\/doi.org\/10.1039\/B512310K (2007).","journal-title":"Chem. Soc. Rev."},{"key":"43985_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115372","volume":"137","author":"GJR Cook","year":"2020","unstructured":"Cook, G. J. R. Imaging with radiolabelled bisphosphonates. Bone 115372. https:\/\/doi.org\/10.1016\/j.bone.2020.115372 (2020).","journal-title":"Bone"},{"key":"43985_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.semnuclmed.2023.07.004","volume":"54","author":"N Mohseninia","year":"2024","unstructured":"Mohseninia, N. et al. Bone metastasis in prostate cancer: Bone scan versus PET imaging. Semin. Nucl. Med. 54, 97\u2013118. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.07.004 (2024).","journal-title":"Semin. Nucl. Med."},{"key":"43985_CR8","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.2967\/jnumed.115.162610","volume":"56","author":"R Minamimoto","year":"2015","unstructured":"Minamimoto, R. et al. Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET\/CT, and whole-body MRI in patients with breast and prostate cancer. J. Nucl. Med. 56, 1862\u20131868. https:\/\/doi.org\/10.2967\/jnumed.115.162610 (2015).","journal-title":"J. Nucl. Med."},{"key":"43985_CR9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.nucmedbio.2012.04.007","volume":"39","author":"M Fellner","year":"2012","unstructured":"Fellner, M. et al. 68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nucl. Med. Biol. 39, 993\u2013999. https:\/\/doi.org\/10.1016\/j.nucmedbio.2012.04.007 (2012).","journal-title":"Nucl. Med. Biol."},{"key":"43985_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41149-7","volume":"13","author":"GP Keeling","year":"2023","unstructured":"Keeling, G. P. et al. 68Ga-bisphosphonates for the imaging of extraosseous calcification by positron emission tomography. Sci. Rep. 13, 14611. https:\/\/doi.org\/10.1038\/s41598-023-41149-7 (2023).","journal-title":"Sci. Rep."},{"key":"43985_CR11","doi-asserted-by":"publisher","first-page":"12766","DOI":"10.1038\/s41598-025-97920-5","volume":"15","author":"L Li","year":"2025","unstructured":"Li, L. et al. Comparison of 18F-FDG and 68Ga-DOTA-IBA in detecting bone metastases: a lesion-basis study. Sci. Rep. 15, 12766. https:\/\/doi.org\/10.1038\/s41598-025-97920-5 (2025).","journal-title":"Sci. Rep."},{"key":"43985_CR12","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1021\/acs.molpharmaceut.0c00103","volume":"17","author":"Z Zha","year":"2020","unstructured":"Zha, Z. et al. A new [68Ga]Ga-HBED-CC-bisphosphonate as a bone imaging agent. Mol. Pharm. 17, 1674\u20131684. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00103 (2020).","journal-title":"Mol. Pharm."},{"key":"43985_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1089\/cbr.2023.0077","volume":"39","author":"S Chakraborty","year":"2024","unstructured":"Chakraborty, S. Synthesis, quality control, and bench-to-bed translation of a new [68Ga]Ga-labeled NOTA-conjugated bisphosphonate for imaging skeletal metastases by positron emission tomography. Cancer Biother. Radiopharm. 39, 92\u2013101. https:\/\/doi.org\/10.1089\/cbr.2023.0077 (2024).","journal-title":"Cancer Biother. Radiopharm."},{"key":"43985_CR14","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1021\/acs.molpharmaceut.6b00582","volume":"13","author":"R Chakravarty","year":"2016","unstructured":"Chakravarty, R., Chakraborty, S. & Dash, A. 64Cu2+ ions as PET probe: An emerging paradigm in molecular imaging of cancer. Mol. Pharm. 13, 3601\u20133612. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00582 (2016).","journal-title":"Mol. Pharm."},{"key":"43985_CR15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s12149-020-01522-2","volume":"34","author":"R Chakravarty","year":"2020","unstructured":"Chakravarty, R. et al. Reactor produced [64Cu]CuCl2 as a PET radiopharmaceutical for cancer imaging: From radiochemistry laboratory to nuclear medicine clinic. Ann. Nucl. Med. 34, 899\u2013910. https:\/\/doi.org\/10.1007\/s12149-020-01522-2 (2020).","journal-title":"Ann. Nucl. Med."},{"key":"43985_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1515\/ract-2023-0206","volume":"112","author":"S Patra","year":"2024","unstructured":"Patra, S. et al. Preparation of [64Cu]Cu\u2013NOTA complex as a potential renal PET imaging agent using 64Cu produced via the direct activation route. Radiochim. Acta. 112, 545\u2013551. https:\/\/doi.org\/10.1515\/ract-2023-0206 (2024).","journal-title":"Radiochim. Acta."},{"key":"43985_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/ph10020045","volume":"10","author":"N Pfannkuchem","year":"2017","unstructured":"Pfannkuchem, N. et al. Novel radiolabeled bisphosphonates for PET diagnosis and endoradiotherapy of bone metastases. Pharmaceuticals 10, 45. https:\/\/doi.org\/10.3390\/ph10020045 (2017).","journal-title":"Pharmaceuticals"},{"key":"43985_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13550-016-0161-3","volume":"6","author":"R Bergmann","year":"2016","unstructured":"Bergmann, R. et al. 177Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment. EJNMMI Res. 6, 5. https:\/\/doi.org\/10.1186\/s13550-016-0161-3 (2016).","journal-title":"EJNMMI Res."},{"key":"43985_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1515\/ract-2019-3219","volume":"108","author":"S Chakraborty","year":"2020","unstructured":"Chakraborty, S. et al. Formulation of \u2018ready-to-use\u2019 human clinical doses of 177Lu-labeled bisphosphonate amide of DOTA using moderate specific activity 177Lu and its preliminary evaluation in human patient. Radiochim Acta. 108, 661\u2013572. https:\/\/doi.org\/10.1515\/ract-2019-3219 (2020).","journal-title":"Radiochim Acta"},{"key":"43985_CR20","doi-asserted-by":"publisher","first-page":"127115","DOI":"10.1016\/j.matchemphys.2022.127115","volume":"295","author":"S Patra","year":"2023","unstructured":"Patra, S. et al. Radiolabeled porous hydroxyapatite microspheres: an advanced material for potential use in radiation synovectomy. Mater. Chem. Phys. 295, 127115. https:\/\/doi.org\/10.1016\/j.matchemphys.2022.127115 (2023).","journal-title":"Mater. Chem. Phys."},{"key":"43985_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/jlcr.3517","volume":"60","author":"S Chakraborty","year":"2017","unstructured":"Chakraborty, S. et al. A mix-and\u2010use approach for formulation of human clinical doses of 177Lu\u2010DOTMP at hospital radiopharmacy for management of pain arising from skeletal metastases. J. Label. Compd. Radiopharm. 60, 410\u2013419. https:\/\/doi.org\/10.1002\/jlcr.3517 (2017).","journal-title":"J. Label. Compd. Radiopharm"},{"key":"43985_CR22","doi-asserted-by":"publisher","first-page":"91723","DOI":"10.1039\/C5RA17266G","volume":"5","author":"R Chakravarty","year":"2015","unstructured":"Chakravarty, R. et al. 64CuCl2 produced by direct neutron activation route as a cost-effective probe for cancer imaging: the journey has begun. RSC Adv. 5, 91723. https:\/\/doi.org\/10.1039\/C5RA17266G (2015).","journal-title":"RSC Adv."},{"key":"43985_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.115.156539","volume":"56","author":"A Pfeifer","year":"2015","unstructured":"Pfeifer, A. et al. 64Cu-DOTATATE PET for neuroendocrine tumors: A prospective head-to-head comparison with 111In-DTPA-Octreotide in 112 patients. J. Nucl. Med. 56, 847\u2013854. https:\/\/doi.org\/10.2967\/jnumed.115.156539 (2015).","journal-title":"J. Nucl. Med."},{"key":"43985_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.contraception.2009.12.003","volume":"81","author":"CA Grillo","year":"2010","unstructured":"Grillo, C. A., Reigosa, M. A. & de Mele, M. F. L. Does over-exposure to copper ions released from metallic copper induce cytotoxic and genotoxic effects on mammalian cells? Contraception 81, 343\u2013349. https:\/\/doi.org\/10.1016\/j.contraception.2009.12.003 (2010).","journal-title":"Contraception"},{"key":"43985_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41181-020-00119-4","volume":"6","author":"H Yang","year":"2021","unstructured":"Yang, H. et al. Synthesis of DOTA-pyridine chelates for 64Cu coordination and radiolabeling of \u03b1MSH peptide. EJNMMI Radiopharm Chem. 6, 3. https:\/\/doi.org\/10.1186\/s41181-020-00119-4 (2021).","journal-title":"EJNMMI Radiopharm Chem."},{"key":"43985_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5004\/dwt.2012.3000","volume":"39","author":"VJ Inglezakis","year":"2012","unstructured":"Inglezakis, V. J. & Zorpas, A. A. Heat of adsorption, adsorption energy and activation energy in adsorption and ion exchange systems. Desalin. Water Treat. 39, 149\u2013157 (2012).","journal-title":"Desalin. Water Treat."},{"key":"43985_CR27","doi-asserted-by":"publisher","first-page":"110092","DOI":"10.1016\/j.apradiso.2021.110092","volume":"181","author":"HE Ramadan","year":"2022","unstructured":"Ramadan, H. E., El-Amir, M. A. & Mostafa, M. Adsorption studies of molybdate(VI)\u201399Mo onto nano zirconium hydroxide gel. Appl. Radiat. Isot. 181, 110092. https:\/\/doi.org\/10.1016\/j.apradiso.2021.110092 (2022).","journal-title":"Appl. Radiat. Isot."},{"key":"43985_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/cbr.2018.2605","volume":"34","author":"M Guleria","year":"2019","unstructured":"Guleria, M. et al. Convenient formulation of 68Ga-BPAMD patient dose using lyophilized BPAMD kit and 68Ga sourced from different commercial generators for imaging of skeletal metastases. Cancer Biother Radiopharm. 34, 67\u201375. https:\/\/doi.org\/10.1089\/cbr.2018.2605 (2019).","journal-title":"Cancer Biother Radiopharm"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43985-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43985-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43985-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:39:52Z","timestamp":1780443592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43985-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43985"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43985-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17074"}}